That is a minuscule amount of liquid, barely a droplet, and extremely difficult to measure accurately on a standard insulin syringe
Ozempic offered a way out
A 2025 meta-analysis examining over 142,000 participants found that tirzepatide produced significantly greater weight loss than semaglutide, an average of 4.23% more body weight lost
Common areas include the calves, thighs, feet, hands, or back
It is metabolically active tissue that produces inflammatory signals, worsens insulin resistance, and increases cardiovascular risk
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs